Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.

Catumaxomab, the first anti-EpCAM antibody, was approved in 2009 for the treatment of malignant ascites in cancer patients with EpCAM positive tumors...
487KB Sizes 0 Downloads 0 Views

Recommend Documents

No documents